GB201002224D0 - Respiratory disease treatment - Google Patents

Respiratory disease treatment

Info

Publication number
GB201002224D0
GB201002224D0 GBGB1002224.2A GB201002224A GB201002224D0 GB 201002224 D0 GB201002224 D0 GB 201002224D0 GB 201002224 A GB201002224 A GB 201002224A GB 201002224 D0 GB201002224 D0 GB 201002224D0
Authority
GB
United Kingdom
Prior art keywords
respiratory disease
disease treatment
treatment
respiratory
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1002224.2A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Argenta Therapeutics Ltd
Original Assignee
Argenta Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argenta Therapeutics Ltd filed Critical Argenta Therapeutics Ltd
Priority to GBGB1002224.2A priority Critical patent/GB201002224D0/en
Publication of GB201002224D0 publication Critical patent/GB201002224D0/en
Priority to PCT/GB2011/050224 priority patent/WO2011098799A2/en
Ceased legal-status Critical Current

Links

GBGB1002224.2A 2010-02-10 2010-02-10 Respiratory disease treatment Ceased GB201002224D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1002224.2A GB201002224D0 (en) 2010-02-10 2010-02-10 Respiratory disease treatment
PCT/GB2011/050224 WO2011098799A2 (en) 2010-02-10 2011-02-09 Respiratory disease treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1002224.2A GB201002224D0 (en) 2010-02-10 2010-02-10 Respiratory disease treatment

Publications (1)

Publication Number Publication Date
GB201002224D0 true GB201002224D0 (en) 2010-03-31

Family

ID=42110492

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1002224.2A Ceased GB201002224D0 (en) 2010-02-10 2010-02-10 Respiratory disease treatment

Country Status (2)

Country Link
GB (1) GB201002224D0 (en)
WO (1) WO2011098799A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
JP6800013B2 (en) 2013-03-14 2020-12-16 ポクセル・ソシエテ・アノニムＰｏｘｅｌ ＳＡ Deuterated 2,4-thiazolidinedione and treatment methods
US10188639B2 (en) 2014-01-15 2019-01-29 Deuterx, Llc Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
US20170368150A1 (en) * 2014-09-08 2017-12-28 Gotham Biopharmaceuticals, Inc. Methods of treating pulmonary sarcoidosis
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6235216A (en) 1985-08-09 1987-02-16 Noritoshi Nakabachi Method and device for measuring thickness of heterogeneous material layer nondestructively
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
WO1993018007A1 (en) 1992-03-13 1993-09-16 Tokyo Tanabe Company Limited Novel carbostyril derivative
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
WO2000021143A1 (en) 1998-10-05 2000-04-13 Osram Opto Semiconductors Gmbh & Co. Ohg Radiation emitting semiconductor chip
SI20116A (en) 1998-12-02 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Novel procedure of preparation of simvastatine and its analogues
US6204288B1 (en) 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
GB9908647D0 (en) 1999-04-15 1999-06-09 Smithkline Beecham Plc Novel compounds
US6683115B2 (en) 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
CZ20023537A3 (en) 2000-04-27 2003-02-12 Boehringer Ingelheim Pharma Kg Beta mimetics, process of their preparation and use as a pharmaceutical preparation
DE10346940B3 (en) 2003-10-06 2005-06-16 Schering Ag Substituted pentanols, their use for the preparation of medicaments, in particular anti-inflammatories and pharmaceutical compositions containing them
AU7649701A (en) 2000-08-05 2002-02-18 Glaxo Group Ltd 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
AU2001288271A1 (en) 2000-08-17 2002-02-25 Harrihar A. Pershadsingh Methods for treating inflammatory diseases
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
ATE365720T1 (en) 2001-03-08 2007-07-15 Glaxo Group Ltd AGONISTS OF BETA-ADRENORECEPTORS
ES2296923T3 (en) 2001-03-22 2008-05-01 Glaxo Group Limited FORMANILID DERIVATIVES AS AGONISTS OF THE BETA2 ADRENORRECEPTOR.
DE60227254D1 (en) 2001-06-12 2008-08-07 Glaxo Group Ltd NEW ANTI INFLAMMATORY 17.ALPHA.-HETEROCYCLIC ESTERS OF 17.BETA.-CARBOTHIOAT ANDROSTAN DERIVATIVES
PL211953B1 (en) 2001-09-14 2012-07-31 Glaxo Group Ltd Phenethanolamine derivatives for treatment of respiratory diseases
WO2003042229A1 (en) 2001-11-12 2003-05-22 Glaxo Group Limited Non-aromatic heterocyclic esters of furan-2-one-esters of 17.beta.-carboxyl or 17.beta.-carbothio glucocorticoids
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
WO2003048181A1 (en) 2001-12-01 2003-06-12 Glaxo Group Limited 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
WO2003062259A2 (en) 2002-01-21 2003-07-31 Glaxo Group Limited Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
AU2003222841A1 (en) 2002-04-25 2003-11-10 Glaxo Group Limited Phenethanolamine derivatives
JP2005527618A (en) 2002-05-28 2005-09-15 セラヴァンス インコーポレーテッド Alkoxyaryl β2 adrenergic receptor agonist
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
PE20050130A1 (en) 2002-08-09 2005-03-29 Novartis Ag ORGANIC COMPOUNDS
GB0220730D0 (en) 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
DE10246374A1 (en) 2002-10-04 2004-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 4-(2-alkylamino-1-hydroxyethyl)-3-alkoxy-benzene-1,2-diol derivatives, are beta-mimetics having a long duration of action, useful e.g. for treating asthma, chronic obstructive pulmonary disease or arrhythmia
JP4490911B2 (en) 2002-10-11 2010-06-30 ファイザー・インク Indole derivatives as β-2 agonists
EP1440966A1 (en) 2003-01-10 2004-07-28 Pfizer Limited Indole derivatives useful for the treatment of diseases
DE60315492T2 (en) 2002-10-22 2008-04-24 Glaxo Group Ltd., Greenford MEDICALLY USEFUL ARYLETHANOLAMINE COMPOUNDS
GB0225030D0 (en) 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
EP1556342B1 (en) 2002-10-28 2008-03-26 Glaxo Group Limited Phenethanolamine derivative for the treatment of respiratory diseases
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
DE10253220A1 (en) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 2-(N-phenylalkyl-amino)-1-phenyl-ethanol derivatives, are beta-adrenergic agents especially useful for treating inflammatory and obstructive respiratory diseases such as asthma or COPD
DE10253282A1 (en) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Treatment of chronic obstructive pulmonary disease, using new or known N-substituted 2-amino-1-(benz-(1,4)-oxazin-3-on-8-yl)-ethanol derivative beta-mimetic agents, suitable for once-daily administration
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
DE10258695A1 (en) 2002-12-16 2004-06-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 2-(2-hydroxy-2-(3-methylsulfonylamino-4-hydroxyphenyl)ethylamino-4-(pyrid-2-ylamino)-2-methylbutane used e.g. for treating asthma and chronic obstructive pulmonary disease
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
EP1460064A1 (en) 2003-03-14 2004-09-22 Pfizer Limited Indole-2-carboxamide derivatives useful as beta-2 agonists
US7317102B2 (en) 2003-04-01 2008-01-08 Theravance, Inc. Diarylmethyl and related compounds
US7745462B2 (en) 2003-04-04 2010-06-29 Novartis Ag Quinoline-2-one derivatives for the treatment of airways diseases
US7268147B2 (en) 2003-05-15 2007-09-11 Pfizer Inc Compounds useful for the treatment of diseases
EP1477167A1 (en) 2003-05-15 2004-11-17 Pfizer Limited [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists
JP4616264B2 (en) 2003-05-28 2011-01-19 セラヴァンス， インコーポレーテッド Azabicycloalkane compounds as muscarinic receptor antagonists
JP2006526604A (en) 2003-06-04 2006-11-24 ファイザー・インク 2-Amino-pyridine derivatives as β-2 adrenergic receptor agonists
GB0312832D0 (en) 2003-06-04 2003-07-09 Pfizer Ltd 2-amino-pyridine derivatives useful for the treatment of diseases
EP1638945A1 (en) 2003-07-01 2006-03-29 Schering Aktiengesellschaft Heterocyclically substituted pentanol derivatives, method for the production thereof, and use thereof as anti-inflammatory agents
WO2005033121A2 (en) 2003-10-03 2005-04-14 King Pharmaceuticals Research & Development, Inc. Synthesis of 2-aralkyloxyadenosines, 2-alkoxyadenosines, and their analogs
DE10347385A1 (en) 2003-10-08 2005-05-12 Schering Ag Rearranged pentanols, a process for their preparation and their use as anti-inflammatory agents
JP4638438B2 (en) 2003-10-08 2011-02-23 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト Tetrahydronaphthalene derivatives, methods for their production and their use as anti-inflammatory agents
GB0323701D0 (en) 2003-10-09 2003-11-12 Glaxo Group Ltd Formulations
GB0324654D0 (en) 2003-10-22 2003-11-26 Glaxo Group Ltd Medicinal compounds
GB0324886D0 (en) 2003-10-24 2003-11-26 Glaxo Group Ltd Medicinal compounds
GB0328490D0 (en) 2003-12-09 2004-01-14 Glaxo Group Ltd Medicinal compounds
GB0329182D0 (en) 2003-12-17 2004-01-21 Glaxo Group Ltd Chemical compounds
US7628908B2 (en) 2003-12-19 2009-12-08 Shell Oil Company Systems, methods, and catalysts for producing a crude product
DE102004001413A1 (en) 2004-01-09 2005-08-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-hydroxymethyl-4-hydroxy-phenyl derivatives for the treatment of chronic obstructive pulmonary disease
TW200531692A (en) 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
RS50561B (en) 2004-01-22 2010-05-07 Pfizer Inc. Sulfonamide derivatives for the treatment of diseases
CN1910144B (en) 2004-01-22 2010-06-09 辉瑞大药厂 Sulfonamide derivatives for the treatment of diseases
DE102004003428A1 (en) 2004-01-23 2005-08-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg New long-acting beta-2 agonists, and their use as pharmaceuticals
CA2552871A1 (en) 2004-02-14 2005-08-25 Boehringer Ingelheim International Gmbh Novel, sustained-action beta-2-agonists and their use as medicaments
WO2005092861A1 (en) 2004-03-11 2005-10-06 Pfizer Limited Quinolinone derivatives pharmaceutical compositions containing them and their use
EP1577306A1 (en) 2004-03-17 2005-09-21 Boehringer Ingelheim Pharma GmbH & Co.KG novel benzoxazinone derivatives as slow-acting betamimetics and use thereof in treatment of respiratory tract diseases
EP1577292A1 (en) 2004-03-17 2005-09-21 Pfizer Limited Phenylaminoethanol derivatives as beta2 receptor agonists
HN2004000023A (en) 2004-03-22 2007-11-23 Mars Inc ANIMAL MASCADURE
WO2005092860A1 (en) 2004-03-23 2005-10-06 Pfizer Limited Compounds for the treatment of diseases
PL1730103T3 (en) 2004-03-23 2010-10-29 Pfizer Formamide derivatives useful as adrenoceptor
WO2005092841A1 (en) 2004-03-23 2005-10-06 Pfizer Limited Compounds having beta-agonist activity
CA2560368A1 (en) 2004-03-23 2005-10-06 Pfizer Inc. Compounds for the treatment of diseases
CA2565243A1 (en) 2004-05-13 2005-11-24 Boehringer Ingelheim International Gmbh Hydroxy-substituted benzo-condensed heterocycles for use as beta agonists in the treatment of respiratory diseases
EP1595873A1 (en) 2004-05-13 2005-11-16 Boehringer Ingelheim Pharma GmbH & Co.KG Substituted cycloalkyl derivatives for the treatment of respiratory diseases
DE102004024451A1 (en) 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder formulations for inhalation containing enantiomerically pure beta agonists
DE102004024454A1 (en) 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel enantiomerically pure beta agonists, process for their preparation and their use as pharmaceuticals
EP1751086A2 (en) 2004-06-03 2007-02-14 Theravance, Inc. DIAMINE ß2 ADRENERGIC RECEPTOR AGONISTS
JP2008507532A (en) 2004-07-21 2008-03-13 セラヴァンス， インコーポレーテッド Diaryl ether β2 adrenergic receptor agonist
WO2006016245A1 (en) 2004-08-05 2006-02-16 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
US7566785B2 (en) 2004-09-10 2009-07-28 Theravance, Inc. Amidine substituted aryl aniline compounds
DE102004045648A1 (en) 2004-09-21 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg New betamimetics for the treatment of respiratory diseases
WO2006051373A1 (en) 2004-11-12 2006-05-18 Pfizer Limited Compounds for the treatment of diseases
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
TW200745099A (en) 2006-03-02 2007-12-16 Sankyo Co Optically active thiazolidinedione derivatives
CA2646170A1 (en) * 2006-03-16 2007-09-27 Metabolic Solutions Development Company Combination therapies of thiazolidinedione analogues and glucocorticoid agonists
AU2007227581B2 (en) 2006-03-16 2012-11-08 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease
GB0702458D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 668
GB0702459D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 669
GB0704000D0 (en) 2007-03-01 2007-04-11 Astrazeneca Ab Salts 670
PT2222272E (en) * 2008-08-07 2013-01-29 Pulmagen Therapeutics Inflammation Ltd Respiratory disease treatment
WO2010150014A1 (en) * 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment

Also Published As

Publication number Publication date
WO2011098799A2 (en) 2011-08-18
WO2011098799A3 (en) 2015-09-11

Similar Documents

Publication Publication Date Title
EP2629736A4 (en) Tissue treatment
EP2621588A4 (en) Methods and compositions for disease treatment using inhalation
GB2465897B (en) Respiratory disease treatment
EP2793986A4 (en) Respiratory treatment system including physiological sensors
PL2652193T3 (en) Treatment
EP2618878A4 (en) Therapeutic vaporizer
ZA201205829B (en) Treatment of respiratory disorders
EP2679140A4 (en) Medical endoscope system
GB201002243D0 (en) Respiratory disease treatment
EP2544686A4 (en) Combination methods for treatment of disease
EP2861244A4 (en) Sleep apnea treatment
GB201015822D0 (en) Medical ruggedised case
GB201002224D0 (en) Respiratory disease treatment
GB201013573D0 (en) Treatment
EP2601954A4 (en) Therapeutic agent for disease
IL232239A0 (en) Medical use
IL228589A0 (en) Therapeutic treatment
ZA201207696B (en) Compound for treatment of respiratory condition or disease
GB201014097D0 (en) Treatment
GB201002235D0 (en) Respiratory disease treatment
GB201001903D0 (en) Respiratory disease treatment
GB201001893D0 (en) Respiratory disease treatment
GB0901831D0 (en) Respiratory disease treatment
GB0910944D0 (en) Respiratory disease treatment
GB0901832D0 (en) Respiratory disease treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)